Published in Clin Exp Metastasis on December 05, 2007
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol (2012) 2.58
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Role of NF-κB in the skeleton. Cell Res (2010) 1.45
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res (2013) 1.08
Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov (2012) 1.04
A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. PLoS One (2008) 1.02
Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol (2012) 1.02
A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. Dis Model Mech (2014) 1.00
Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PLoS One (2010) 0.96
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
Targeting RANKL in metastasis. Bonekey Rep (2014) 0.95
Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol (2014) 0.92
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol (2014) 0.91
Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis. J Pediatr Surg (2009) 0.91
Therapeutic implications of osteoprotegerin. Cancer Cell Int (2009) 0.89
Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol Spectr (2016) 0.88
RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol (2008) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Musculoskeletal molecular imaging: a comprehensive overview. Trends Biotechnol (2010) 0.86
Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Int (2012) 0.84
Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporos Int (2011) 0.83
Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep (2014) 0.83
Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer. Cancer Gene Ther (2010) 0.82
Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res (2009) 0.82
Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway. Mol Cancer Res (2010) 0.82
Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. Br J Pharmacol (2012) 0.81
Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases. Mol Cancer (2014) 0.80
High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. Pediatr Res (2012) 0.79
Denosumab: A comprehensive review. South Asian J Cancer (2013) 0.79
In silico analysis of combinatorial microRNA activity reveals target genes and pathways associated with breast cancer metastasis. Cancer Inform (2011) 0.79
Effects of proteasome inhibitors on bone cancer. Bonekey Rep (2013) 0.77
Inhibition of osteoclastogenesis by RNA interference targeting RANK. BMC Musculoskelet Disord (2012) 0.77
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. J Clin Med (2014) 0.75
Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model. Lab Invest (2013) 0.75
Topical Treatment with Xiaozheng Zhitong Paste (XZP) Alleviates Bone Destruction and Bone Cancer Pain in a Rat Model of Prostate Cancer-Induced Bone Pain by Modulating the RANKL/RANK/OPG Signaling. Evid Based Complement Alternat Med (2015) 0.75
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment? J Clin Med (2013) 0.75
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene (2017) 0.75
Inhibition of osteolytic bone metastasis by unfractionated heparin. Clin Exp Metastasis (2008) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Skeletal complications of malignancy. Cancer (1997) 5.41
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res (1995) 1.97
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology (2005) 1.78
The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev (2006) 1.73
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res (2005) 1.65
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res (1999) 1.47
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res (2001) 1.44
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood (2003) 1.44
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res (2003) 1.41
Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res (2005) 1.33
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone (1994) 1.31
RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol (2002) 1.10
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol (2007) 1.06
Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res (2001) 0.99
Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line. Biomed Res (2005) 0.80
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Rapid skeletal turnover in a radiographic mimic of osteopetrosis. J Bone Miner Res (2014) 2.00
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res (2012) 1.98
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood (2002) 1.84
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology (2005) 1.78
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70
Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res (2009) 1.68
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res (2010) 1.65
Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol (2003) 1.56
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem (2002) 1.54
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther (2010) 1.53
Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol (1985) (2008) 1.49
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate (2008) 1.42
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res (2003) 1.33
Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem (2004) 1.30
Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res (2013) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum (2009) 1.27
Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol (2009) 1.23
Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res (2006) 1.18
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone (2008) 1.18
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res (2002) 1.17
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol (2010) 1.16
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther (2008) 1.13
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res (2005) 1.11
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem (2010) 1.10
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res (2003) 1.10
RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol (2007) 1.08
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev (2007) 1.08
Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther (2012) 1.06
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res (2008) 1.06
Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. J Bone Miner Res (2007) 1.05
Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res (2011) 1.05
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res (2005) 1.04
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum (2005) 1.02
Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. I. Immune population distributions. J Appl Physiol (1985) (2003) 1.02
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology (2011) 1.00
One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res (2009) 0.99
New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification. J Bone Miner Res (2009) 0.99
Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res (2003) 0.99
Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis (2013) 0.99
Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone (2009) 0.98
Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement. Bone (2007) 0.98
Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts. J Biol Chem (2007) 0.98
Transient muscle paralysis degrades bone via rapid osteoclastogenesis. FASEB J (2011) 0.97
Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone (2004) 0.97
Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum (2009) 0.97
Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum (2005) 0.96
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res (2013) 0.94
RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat (2014) 0.93
Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. II. Activation, cytokines, erythrocytes, and platelets. J Appl Physiol (1985) (2002) 0.93
Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody. Calcif Tissue Int (2012) 0.93
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood (2002) 0.91
RANKL inhibition: from mice to men (and women). Adv Exp Med Biol (2007) 0.90
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate (2013) 0.89
Regulatory effects of novel neurotrophin-1/b cell-stimulating factor-3 (cardiotrophin-like cytokine) on B cell function. J Immunol (2002) 0.89
Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone (2011) 0.89
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol (2007) 0.87
Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res (2013) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87